STEPHAN SIMONIAN: Open Payments
NPI 1104924208 · GLENDALE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,899 in 103 payments from 12 companies in 2025. Trend: 2023 $3,022 · 2024 $2,234 · 2025 $2,899
Food & beverage: $2,899
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 13 | $502 |
| Vanda Pharmaceuticals Inc. | 16 | $492 |
| Alkermes, Inc. | 12 | $415 |
| ABBVIE INC. | 15 | $383 |
| Otsuka America Pharmaceutical, Inc. | 18 | $333 |
| Janssen Pharmaceuticals, Inc | 10 | $325 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $149 |
| Axsome Therapeutics, Inc. | 3 | $90 |
| Almatica Pharma LLC | 3 | $74 |
| Luye Pharma (USA) Ltd. | 3 | $57 |
Products named: COBENFY, HETLIOZ, VRAYLAR, INVEGA SUSTENNA, ARISTADA, REXULTI, CAPLYTA, LYBALVI.
Industry payments across CA — which companies pay providers there.
